Showing results (221-230 of 232) with videos related to
Sort By:
Pageof 24
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.The Lancet. Neurology|September 20, 2025
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Daniel S Reich, Jiwon Oh, et al.JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.European Journal of Neurology|December 11, 2020
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre studyMaria Di Gregorio, Valentina Liliana Adriana Torri Clerici, Giuseppe Fenu, et al.Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.JAMA Neurology|November 27, 2023
Multiple Sclerosis Progression and Relapse Activity in ChildrenPietro Iaffaldano, Emilio Portaccio, Giuseppe Lucisano, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2026
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.Pageof 24